Second-order map
Exploratory — reasoned, hypothetical relationships for research, not investment advice.
- LLYCatalyst
Eli Lilly
Q2 2026 print on Mounjaro/Zepbound plus first full-quarter read on oral GLP-1 Foundayo (orforglipron) makes oral delivery a primary competitive axis, triggering an industry-wide wave of NDA filings and formulation work
- CERTSpotlight subject
Certara
Primary subject: biosimulation and model-informed regulatory science sits at the filing bottleneck; expedited pharmacometrics submission service is structurally more valuable when multiple sponsors file oral/next-gen GLP-1 formulations concurrently
- SLP
Simulations Plus
Peer in PBPK/biosimulation and formulation modeling; same concurrent-filing workload tailwind could lift demand for predictive-science tools used to optimize oral absorption
- SDGR
Schrodinger
If next-gen GLP-1 race shifts to novel oral small molecules, physics-based molecular design platforms become upstream beneficiaries of the formulation-optimization surge
- MEDP
Medpace
CRO handling the clinical trials behind each new oral GLP-1 filing; a multi-sponsor filing wave implies more concurrent trial execution demand
Veeva Systems
Regulatory submission and eCTD document-management software underpins the actual NDA filing machinery each concurrent filer must activate
- CTLT
Catalent
Direct operational beneficiary: oral GLP-1 formulations shift manufacturing from injectable fill-finish toward oral solid-dose and bioavailability-enhancement CDMO work that sponsors outsource
Lonza Group
Large-scale CDMO capacity; if oral GLP-1 volumes scale, outsourced API and formulation manufacturing demand broadens beyond any single sponsor
- TMO
Thermo Fisher Scientific
Supplier of analytical instrumentation and lab services needed for formulation characterization and bioequivalence testing across many concurrent oral programs
- DHR
Danaher
Bioprocess and analytical tools arm supports the testing and QC workload that scales with a multi-sponsor oral-formulation filing cycle
- ICLR
ICON plc
Second-order beneficiary: contract research organization running the bioavailability, PK and pivotal studies required for each oral GLP-1 NDA, a workload that compounds when filings cluster
- IQV
IQVIA Holdings
Combines CRO trial execution with regulatory analytics and real-world data; concurrent oral GLP-1 development broadens demand across both segments
- CRL
Charles River Laboratories
Preclinical safety and ADME/tox services feed the front end of each new formulation program before it reaches the filing stage
- A
Agilent Technologies
Analytical chemistry instruments for dissolution and bioequivalence testing see broader utilization as oral formulation programs multiply
Take it further
Copy the analysis below into your own AI tool to pressure-test the reasoning and push it further.
Today's crowd trade is straightforward — investors will be closely watching the sales performance of Mounjaro and Zepbound when Eli Lilly reports its second-quarter 2026 results alongside the first commercial read on Foundayo (orforglipron), which launched in April and receives its first full-quarter commercial update today. The headline machinery around Eli Lilly is loud, but the durable second-order read belongs one step removed — in the biosimulation and regulatory science infrastructure that every competing GLP-1 filer must now activate. Oral delivery, not just higher numbers, is now a primary axis of competition , which means a wave of new NDA filings and formulation optimization work is not a distant possibility but an imminent workflow burden across the industry. Certara sits precisely at that bottleneck: from molecule to market, Certara integrates science, technology, strategic and regulatory expertise, and navigates complex regulatory landscapes with AI-driven tools while reducing development risk through predictive science and model-informed strategies . Certara recently launched an expedited Pharmacometrics regulatory submission service that cuts submission timelines in half — a capability that is structurally more valuable in a race where multiple sponsors are filing oral and next-generation GLP-1 formulations concurrently than in any single-drug cycle.